International Immunopharmacology, Journal Year: 2024, Volume and Issue: 143, P. 113588 - 113588
Published: Nov. 17, 2024
Language: Английский
Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)
Published: Sept. 9, 2024
Language: Английский
Citations
40
Experimental Hematology and Oncology, Journal Year: 2024, Volume and Issue: 13(1)
Published: Aug. 6, 2024
Abstract The tumor microenvironment demonstrates great immunophenotypic heterogeneity, which has been leveraged in traditional immune-hot/cold categorization based on the abundance of intra-tumoral immune cells. By incorporating spatial contexture, immunophenotype was further elaborated into immune-inflamed, immune-excluded, and immune-desert. However, mechanisms underlying these different phenotypes are yet to be comprehensively elucidated. In this review, we discuss how cells interact collectively shape landscape from perspectives cells, extracellular matrix, cancer metabolism, summarize potential therapeutic options according distinct immunophenotypes for personalized precision medicine.
Language: Английский
Citations
17
Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)
Published: Jan. 13, 2025
The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, signaling molecules that interact promote growth therapeutic resistance. Elucidating the intricate interactions between cells TME crucial in understanding progression challenges. A critical process induced by epithelial-mesenchymal transition (EMT), wherein epithelial acquire mesenchymal traits, which enhance their motility invasiveness progression. By targeting various components TME, novel investigational strategies aim disrupt TME's contribution EMT, thereby improving efficacy, addressing resistance, offering a nuanced approach therapy. This review scrutinizes key players emphasizing avenues therapeutically components. Moreover, article discusses implications for resistance mechanisms highlights current toward modulation along with potential caveats.
Language: Английский
Citations
16
Biomedicines, Journal Year: 2025, Volume and Issue: 13(3), P. 664 - 664
Published: March 8, 2025
Osteosarcoma (OS) is the predominant mesenchymal primary malignant bone tumor in oncology and pathology, impacting a wide age range from adolescents to older adults. It frequently advances lung metastasis, ultimately resulting mortality of OS patients. The precise pathological pathways responsible for progression dissemination are not fully understood due its heterogeneity. integration surgery with neoadjuvant postoperative chemotherapy has significantly increased 5-year survival rate more than 70% patients localized tumors. However, about 30% experience local recurrence and/or metastasis. Hence, there requirement innovative therapeutic approaches address limitations traditional treatments. Immunotherapy garnered increasing attention as promising avenue tumors resistant standard therapies, including OS, despite underlying mechanisms disease remaining well elucidated. may have been suitable use because tumor’s immunosuppressive microenvironment limited immunogenicity. Nevertheless, immune-based treatments now being developed clinical use, such bispecific antibodies, chimeric antigen receptor T cells, immune checkpoint inhibitors. Also, additional immunotherapy techniques cytokines, vaccines, modified-Natural Killer (NK) cells/macrophages early phases research but will certainly be popular subjects nearest future. Our goal writing this review was spark new lines inquiry into by summarizing findings both preclinical current studies examining different approaches.
Language: Английский
Citations
1
International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(15), P. 12520 - 12520
Published: Aug. 7, 2023
The cure rate for metastatic or relapsed osteosarcoma has not substantially improved over the past decades despite exploitation of multimodal treatment approaches, allowing long-term survival in less than 30% cases. Patients with often develop resistance to chemotherapeutic agents, where personalized targeted therapies should offer new hope. T cell immunotherapy as a complementary alternative modality is advancing rapidly general, but its potential against remains largely unexplored. Strategies incorporating immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) modified cells, and engaging bispecific antibodies (BsAbs) are being explored tackle refractory osteosarcoma. However, an inherently heterogeneous tumor, both at intra- inter-tumor level, no identical driver mutations. It pro-tumoral microenvironment, bone stromal neovasculature, suppressive mineralized extracellular matrix (ECM) combine derail infiltration anti-tumor function. To realize osteosarcoma, integrated approach targeting this complex ecosystem needs smart planning execution. Herein, we review current status immunotherapies summarize challenges encountered, explore combination strategies overcome these hurdles, ultimate goal curing acute side effects.
Language: Английский
Citations
20
Cancers, Journal Year: 2023, Volume and Issue: 15(20), P. 5108 - 5108
Published: Oct. 23, 2023
Osteosarcoma (OS) is a heterogeneous, highly metastatic bone malignancy in children and adolescents. Despite advancements multimodal treatment strategies, the prognosis for patients with or recurrent disease has not improved significantly last four decades. OS heterogeneous tumor; its genetic background mechanism of oncogenesis are well defined. Unfortunately, no effective molecular targeted therapy currently available this disease. Understanding osteosarcoma’s tumor microenvironment (TME) recently gained much interest among scientists hoping to provide valuable insights into heterogeneity, progression, metastasis, identification novel therapeutic avenues. Here, we review current understanding TME OS, including different cellular noncellular components, their crosstalk cells, involvement progression metastasis. We also highlight past/current clinical trials targeting therapies potential future strategies negligible adverse effects.
Language: Английский
Citations
17
EJC Paediatric Oncology, Journal Year: 2024, Volume and Issue: 3, P. 100161 - 100161
Published: April 7, 2024
Neuroblastoma is a cancer of the sympathetic nervous system that develops in young children, either as low-risk or high-risk disease. The tumor microenvironment (TME) now recognized an important player ecosystem may promote drug resistance and immune escape. Targeting TME combination with therapies directly targeting cells therefore represents interesting strategy to prevent emergence improve patient's outcome. development such strategies however requires in-depth understanding landscape, due its high complexity intra inter-tumoral heterogeneity. Various approaches have been used last years characterize non-immune cell populations present tumors neuroblastoma patients, both quantitatively qualitatively, particular use single-cell transcriptomics. It anticipated near future, genomic information will contribute precise approach therapy neuroblastoma.Deciphering mechanisms interaction between stromal key identify novel therapeutic combinations. Over decade, numerous vitro studies vivo pre-clinical experiments immune-competent immune-deficient models identified circumvent Some these formed basis for early phase I II clinical trials children recurrent refractory neuroblastoma. This review summarizes recently published data on characterization landscape various cellular components, molecules pathways activated result tumor-host interactions.
Language: Английский
Citations
7
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2024, Volume and Issue: 1879(5), P. 189176 - 189176
Published: Sept. 1, 2024
Language: Английский
Citations
7
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: Dec. 1, 2023
Recent progressions in immunotherapy have transformed cancer treatment, providing a promising strategy that activates the immune system of patient to find and eliminate cancerous cells. Bispecific antibodies, which engage two separate antigens or one antigen with distinct epitopes, are tremendous concern immunotherapy. The bi-targeting idea enabled by bispecific antibodies (BsAbs) is especially attractive from medical standpoint since most diseases complex, involving several receptors, ligands, signaling pathways. Several research look into processes BsAbs identify different targets such angiogenesis, reproduction, metastasis, regulation. By rerouting cells altering other pathways, proteins perform effector activities addition those natural antibodies. This opens up wide range clinical applications helps patients resistant tumors respond better medication. Yet, further study necessary best conditions where use these medications for treating tumor, their appropriate combination partners, methods reduce toxicity. In this review, we provide insights BsAb format classification based on composition symmetry, as well delivery mode, focus action mechanism molecule, discuss challenges future perspectives development.
Language: Английский
Citations
15
Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15
Published: Jan. 24, 2024
Osteosarcoma (OS) is a malignant tumor originating from mesenchymal tissue. Pulmonary metastasis usually present upon initial diagnosis, and the primary factor affecting poor prognosis of patients with OS. Current research shows that ability to regulate cellular microenvironment essential for preventing distant OS, anoxic microenvironments are important features solid tumors. During hypoxia, hypoxia-inducible factor-1α (HIF-1α) expression levels stability increase. Increased HIF-1α promotes vascular remodeling, epithelial-mesenchymal transformation (EMT), OS cells invasiveness; this leads cells. plays an role in mechanisms metastasis. In order develop precise prognostic indicators potential therapeutic targets treatment, review examines molecular cells; signal transduction pathways mediated by also discussed.
Language: Английский
Citations
6